Form 4: SI-BONE CEO Laura Francis Reports Acquisition of Common Stock and Transfer of Shares to Trust

Laura Francis, CEO of SI-BONE, Inc., reports the acquisition of common stock through restricted stock units and a transfer of shares to The David & Laura Francis Joint Rev Tr.

Summary

• On February 3, 2025, Laura Francis, CEO of SI-BONE, Inc., acquired common stock through the settlement of restricted stock units.
• These restricted stock units vest over time, contingent on continued service and/or the company's performance.
• A total of 122,315 shares were acquired based on time-based vesting, 91,736 shares were acquired based on total shareholder return (TSR), and 30,579 shares were acquired based on 2025 net revenue growth and adjusted EBITDA.
• Francis also transferred 341,462 shares to The David & Laura Francis Joint Rev Tr.
• Following these transactions, Francis directly owns 552,994 shares and indirectly owns 341,462 shares through the trust.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, suggesting a neutral to slightly positive outlook due to the alignment of management incentives with shareholder value.

Positives

• The acquisition of shares by the CEO demonstrates confidence in the company's future performance.
• The vesting of restricted stock units is tied to performance metrics like TSR, net revenue growth, and adjusted EBITDA, aligning management's interests with shareholders.

Future Outlook

The vesting of restricted stock units is contingent upon continued service and the achievement of performance metrics, suggesting an expectation of continued service and company growth.

Industry Context

This filing is a routine disclosure of stock ownership changes by a company executive, which is common in publicly traded companies. The use of restricted stock units as compensation is a standard practice to align executive incentives with shareholder value.

Comparison to Industry Standards

• Stock grants to CEOs are common practice.
• The vesting schedules and performance metrics (TSR, revenue growth, EBITDA) are typical for executive compensation packages.
• Comparing SI-BONE's executive compensation structure to similar medical device companies like NuVasive or Globus Medical would provide further context.

Stakeholder Impact

• Shareholders may view the CEO's stock acquisitions as a positive sign of confidence in the company's future.
• Employees may be motivated by the performance-based vesting of restricted stock units, as it aligns their efforts with company goals.

Key Dates

Keywords

SI-BONE, Laura Francis, restricted stock units, common stock, beneficial ownership, Form 4, TSR, net revenue, adjusted EBITDA, trust